×
About 2,130 results

ALLMedicine™ Langerhans Cell Histiocytosis Center

Research & Reviews  808 results

A Rare Widespread Cutaneous Langerhans Cell Histiocytosis Manifested on 18F-FDG PET/CT.
https://doi.org/10.1097/RLU.0000000000004267
Clinical Nuclear Medicine; Wang L, Zhang Y et. al.

May 12th, 2022 - Widespread cutaneous involvement of Langerhans cell histiocytosis is rare. Here, we report the case of a patient with cutaneous Langerhans cell histiocytosis, which showed a large number of small high 18F-FDG-avid foci all over the body skin on PE...

A common presentation - turning out as uncommon diagnosis: from hip pain to Langerhans ...
https://doi.org/10.1016/j.amjms.2022.04.014
The American Journal of the Medical Sciences; Volis I, Livneh I et. al.

Apr 27th, 2022 - Langerhans cell histiocytosis (LCH) is an uncommon clonal proliferation of myeloid progenitor cells, it is especially rare in adults. We present a case of multi-system LCH in a 53-year-old woman, the sole symptom of which was prolonged, non-resolv...

What is the Role of Different Macrophage Subsets in the Evolution of Juvenile Xanthogra...
https://doi.org/10.1097/PAI.0000000000001029
Applied Immunohistochemistry & Molecular Morphology : AIMM; Wegher LSM, Kazmarek LM et. al.

Apr 19th, 2022 - There are several activated forms of macrophages: 2 main groups are designated M1 and M2. While M1 macrophages have proinflammatory, bactericidal, and phagocytic functions and are the dominant phenotype observed in the early stages of inflammation...

Unique Case of Congenital Langerhans Cell Histiocytosis Presenting as Intrauterine Feta...
https://doi.org/10.1177/10935266221078501
Pediatric and Developmental Pathology : the Official Jour... Baig A, Albrecht S et. al.

Apr 15th, 2022 - Congenital Langerhans cell histiocytosis (LCH) (formerly called Letterer-Siwe disease) is characterized by a clonal proliferation of Langerhans cells occurring in children at birth and manifests typically with multifocal cutaneous lesions, hepatos...

Lung Transplant in a Patient With Multifocal Langerhans Cell Histiocytosis After Chemot...
https://doi.org/10.1016/j.transproceed.2022.02.037
Transplantation Proceedings; Abba ME, Żegleń S et. al.

Apr 13th, 2022 - Langerhans cell histiocytosis (LCH) is a rare inflammatory disorder of myeloid dendritic cells with mutations involving KRAS, BRAF and/or NRAS, and MAP2K1 genes. We describe the case of a 58-year-old female previous smoker with multifocal LCH invo...

see more →

Guidelines  1 results

The Mayo Clinic Histiocytosis Working Group Consensus Statement for the Diagnosis and E...
https://doi.org/10.1016/j.mayocp.2019.02.023
Mayo Clinic Proceedings; Goyal G, Young JR et. al.

Sep 2nd, 2019 - Histiocytic neoplasms, a rare and heterogeneous group of disorders, primarily include Erdheim-Chester disease, Langerhans cell histiocytosis, and Rosai-Dorfman disease. Due to their diverse clinical manifestations, the greatest challenge posed by ...

see more →

Clinicaltrials.gov  15 results

The Efficacy and Safety of HLX208 in Adult Langerhans Cell Histiocytosis (LCH) and Erdheim-Chester Disease (ECD) With BRAF V600E Mutation
https://clinicaltrials.gov/ct2/show/NCT05092815

Jan 4th, 2022 - The purpose of this study was to assess safety, efficacy and PK in adult Langerhans Cell Histiocytosis (LCH) and Erdheim-Chester Disease (ECD) given HLX208 (BRAF V600E inhibitor).

Cobimetinib in Refractory Langerhans Cell Histiocytosis (LCH), and Other Histiocytic Disorders
https://clinicaltrials.gov/ct2/show/NCT04079179

Sep 2nd, 2021 - Histiocytic disorders are diseases caused by misfunctioning or buildup of particular immune cells called histiocytes. Many histiocytic disorders (LCH, juvenile xanthogranuloma (JXG), Erdheim-Chester disease (ECD), and Rosai-Dorfman Disease (RDD)) ...

Dabrafenib and Trametinib in People With BRAF V600E Mutation Positive Lesions in Erdheim Chester Disease
https://clinicaltrials.gov/ct2/show/NCT02281760

Aug 31st, 2021 - Erdheim-Chester Diseases (ECD) is a very rare non-Langerhans cell histiocytosis of unknown origin and pathogenesis. It has been reported mainly in adult males over the age of 40 years, although cases have been reported in females as well. Children...

Vinblastine/Prednisone Versus Single Therapy With Cytarabine for Langerhans Cell Histiocytosis (LCH)
https://clinicaltrials.gov/ct2/show/NCT02670707

Jun 4th, 2021 - To be eligible to participate in this study, patients physician must have determined that they have LCH which is not treatable by surgical intervention or observation alone. If patient chooses to participate in this study, they will be assigned ra...

International Rare Histiocytic Disorders Registry (IRHDR)
https://clinicaltrials.gov/ct2/show/NCT02285582

Mar 9th, 2021 - Histiocytoses are rare diseases caused by an excess of cells called Histiocytes, which can infiltrate the skin, bones, lungs, liver, spleen and the central nervous system. These disorders can range from localized involvement that resolves spontane...

see more →

News  27 results

Treatment of Langerhans Cell Histiocytosis Clinical Practice Guidelines (NCCN, 2021)
https://www.medscape.com/viewarticle/963817

Dec 1st, 2021 - Guidelines for the treatment of Langerhans cell histiocytosis (LCH) were published in November 2021 by the National Comprehensive Cancer Network (NCCN) in Journal of the National Comprehensive Cancer Network.[1] Decisions regarding treatment of LC...

Selumetinib Response Not Driven by MAPK Expression in Pediatric and AYA Refractory Solid Tumors
https://www.onclive.com/view/selumetinib-response-not-driven-by-mapk-expression-in-pediatric-and-aya-refractory-solid-tumors

Jun 10th, 2021 - Selumetinib did not elicit clinical activity in pediatric and young adult patients with refractory cancers who had actionable mutations in the RAS/RAF/MAPK1/2-ERK pathway, according to cohort findings from the phase 2, single-arm National Cancer I...

COG to Assess Targeted Therapies in a Variety of NHL Clinical Trials
https://www.onclive.com/view/cog-to-assess-targeted-therapies-in-a-variety-of-nhl-clinical-trials

Dec 20th, 2020 - Birte Wistinghausen, MD The Children's Oncology Group (COG) is currently involved in 5 studies exploring targeted therapies in non-Hodgkin lymphoma (NHL) that could eventually change the face of pediatric NHL treatment.1 Birte Wistinghausen, MD,...

Radiotherapy in the Modern Era in the Management of Langerhans Cell Histiocytosis
https://www.onclive.com/view/radiotherapy-in-the-modern-era-in-the-management-of-langerhans-cell-histiocytosis

Dec 5th, 2020 - Rupen Garg, BS EXPERT'S PERSPECTIVE: Bradford Hoppe, MD, MPH Associate Professor, University of Florida Proton Therapy Institute Why is this article contemporary? One concern for utilizing radiotherapy (RT) is the potential for toxicity,...

COVID-19 and the Slippery Road of Cytokine Storms
https://www.medpagetoday.com/infectiousdisease/covid19/86021

Apr 19th, 2020 - Early reports on the COVID-19 pandemic allude to a cytokine storm or hyper-inflammation, especially in patients who succumbed to the illness. These conclusions are based on elevated levels of ferritin and other inflammatory markers, drawing compar...

see more →

Patient Education  1 results see all →